Dyne Therapeutics (DYN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.12 (+0.41%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Dyne Therapeutics (DYN)
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Key Insights

Critical company metrics and information
  • Share Price

    $28.82
  • Market Cap

    $2.93 Billion
  • Total Outstanding Shares

    101.77 Million Shares
  • Total Employees

    173
  • Dividend

    No dividend
  • IPO Date

    September 17, 2020
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.dyne-tx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$806.41 Million
Net Cash Flow From Operating Activities, Continuing$-243.04 Million
Net Cash Flow From Operating Activities$-243.04 Million
Net Cash Flow$401.50 Million
Net Cash Flow, Continuing$401.50 Million
Net Cash Flow From Investing Activities$-161.87 Million
Net Cash Flow From Investing Activities, Continuing$-161.87 Million
Net Cash Flow From Financing Activities, Continuing$806.41 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$-314.47 Million
Revenues$0.00
Net Income/Loss Available To Common Stockholders, Basic$-294.51 Million
Basic Earnings Per Share$3.56
Income/Loss From Continuing Operations Before Tax$-294.51 Million
Operating Expenses$314.47 Million
Research and Development$258.45 Million
Income/Loss From Continuing Operations After Tax$-294.51 Million
Net Income/Loss Attributable To Parent$-294.51 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Other Operating Expenses$56.02 Million
Diluted Earnings Per Share$3.56
Net Income/Loss$-294.51 Million
Preferred Stock Dividends And Other Adjustments$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$736.39 Million
Other Current Liabilities$25.79 Million
Assets$768.84 Million
Wages$11.31 Million
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$6.16 Million
Equity$705.54 Million
Liabilities$63.30 Million
Liabilities And Equity$768.84 Million
Fixed Assets$4.90 Million
Noncurrent Assets$32.45 Million
Other Non-current Assets$27.56 Million
Equity Attributable To Parent$705.54 Million
Noncurrent Liabilities$20.04 Million
Current Liabilities$43.26 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.